1280px-epi-pen_1

Mylan agrees $465m settlement over EpiPen misclassification

pharmafile | October 10, 2016 | News story | Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen 

In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the drug’s owner Mylan intentionally misclassified the epinephrine auto-injector under the Medicaid rebate programme. The company has rejected the claims and has agreed to settle the claims with a payment of $465 million.

The claims follow the revelation that Mylan had overcharged the government for the product for years, according to the US Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS). Mylan paid a rebate of 13% of EpiPen’s total list price due to its classification as a non-innovator drug, rather than 23.1% for branded drugs, a move which prompted three US senators to request a Justice Department investigation.

This settlement resolves “all potential rebate liability claims by federal and state governments”, while the company reduces its full-year earnings guidance to $4.70 – $4.90 per share.

“This agreement is another important step in Mylan’s efforts to move forward and bring resolution to all EpiPen Auto-Injector related matters,” commented CEO Heather Bresch. “Entering into this settlement is the right course of action at this time for the company, its stakeholders and the Medicaid programme.” 

Mylan’s shares leapt up by 10% following the news.

Matt Fellows

Related Content

Pfizer to pay $345 million in EpiPen lawsuit

Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …

800px-mono-embolex_by_danny_s

Mylan reaches agreement with Aspen for their European thrombosis business

Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s …

biogen-idec-tecfidera-dimethyl-fumarate

Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …

Latest content